

Eli Lilly vs Novo Nordisk
Major pharmaceutical group with diabetes and obesity medicines vs Global diabetes leader with growing obesity treatment business. Which is the better buy for your portfolio in July 2026? Plain-English answer below.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster drugs, while Novo Nordisk invented the GLP-1 category and built a decades-long diabetes dominance before Lilly arrived to contest it. Both are racing to manufacture, distribute, and expand the clinical use of weight-loss treatments in a market that analysts describe as generational in size. Eli Lilly vs Novo Nordisk is the defining pharmaceutical rivalry of this decade, a head-to-head battle between two innovation machines competing for the same massive patient population.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster...
Why It’s Moving

Lilly stays in focus as analysts back its growth engine, but expectations remain stretched.
- Analyst sentiment remains constructive, with most recent Wall Street coverage still clustered around buy or overweight ratings, keeping expectations elevated even as the stock has already moved sharply this year.
- The latest price-target range is wide, signaling debate over how much of Lilly’s growth story is already priced in and leaving the shares sensitive to any change in outlook.
- Investor attention is still anchored to Lilly’s obesity and diabetes franchise, where future prescription growth and manufacturing scale-up remain the key drivers behind the valuation premium.

Novo Nordisk is drawing renewed attention as analysts bet on a rebound from depressed expectations.
- Analysts continue to see upside in Novo Nordisk as the market prices in a recovery from this year’s sharp reset, with forecasts still clustering above recent trading levels.
- The stock has been weighed down by earlier guidance cuts and a trial setback, so the current debate is less about growth disappearing and more about how quickly expectations can stabilize.
- Recent analyst calls remain mixed but generally constructive, suggesting investors are still willing to pay for Novo Nordisk’s long-term obesity and diabetes franchise despite near-term volatility.

Lilly stays in focus as analysts back its growth engine, but expectations remain stretched.
- Analyst sentiment remains constructive, with most recent Wall Street coverage still clustered around buy or overweight ratings, keeping expectations elevated even as the stock has already moved sharply this year.
- The latest price-target range is wide, signaling debate over how much of Lilly’s growth story is already priced in and leaving the shares sensitive to any change in outlook.
- Investor attention is still anchored to Lilly’s obesity and diabetes franchise, where future prescription growth and manufacturing scale-up remain the key drivers behind the valuation premium.

Novo Nordisk is drawing renewed attention as analysts bet on a rebound from depressed expectations.
- Analysts continue to see upside in Novo Nordisk as the market prices in a recovery from this year’s sharp reset, with forecasts still clustering above recent trading levels.
- The stock has been weighed down by earlier guidance cuts and a trial setback, so the current debate is less about growth disappearing and more about how quickly expectations can stabilize.
- Recent analyst calls remain mixed but generally constructive, suggesting investors are still willing to pay for Novo Nordisk’s long-term obesity and diabetes franchise despite near-term volatility.
Investment Analysis

Eli Lilly
LLY
Pros
- Eli Lilly dominates GLP-1 market with superior U.S. momentum in Mounjaro and Zepbound sales.
- Advanced oral GLP-1 pipeline positions it ahead in next-generation obesity treatments.
- Stronger pricing power and revenue growth outpace Novo Nordisk amid competition.
Considerations
- Intensifying rivalry from Novo Nordisk's oral Wegovy launch erodes market share.
- Regulatory delays for oral candidates heighten execution risks in innovation race.
- Exposure to compounded semaglutide pressures margins and long-term profitability.

Novo Nordisk
NVO
Pros
- Launch of oral Wegovy provides first-to-market edge in convenient GLP-1 formulations.
- Semaglutide patent upheld in China bolsters global intellectual property protection.
- Recent U.S. rollout via Amazon Pharmacy expands Wegovy accessibility and demand.
Considerations
- Declining 2026 earnings estimates signal weakening profitability outlook.
- Intensifying GLP-1 competition from Eli Lilly hampers Ozempic and Wegovy growth.
- Pricing pressures and self-pay discounts raise concerns over margin compression.
Eli Lilly (LLY) Next Earnings Date
The next earnings date for LLY is expected on August 5, 2026 or August 6, 2026, depending on the source, with the most common estimates pointing to August 5, 2026. It will cover Q2 2026 results. For a precise investor calendar, this timing is consistent with Eli Lilly’s typical early-August earnings pattern.
Novo Nordisk (NVO) Next Earnings Date
The next earnings date for NVO is expected on August 5, 2026, though it remains unconfirmed by the company. It is expected to cover Q2 2026 results. The date is consistent with the company’s typical early-August reporting pattern and is scheduled before the market opens.
Eli Lilly (LLY) Next Earnings Date
The next earnings date for LLY is expected on August 5, 2026 or August 6, 2026, depending on the source, with the most common estimates pointing to August 5, 2026. It will cover Q2 2026 results. For a precise investor calendar, this timing is consistent with Eli Lilly’s typical early-August earnings pattern.
Novo Nordisk (NVO) Next Earnings Date
The next earnings date for NVO is expected on August 5, 2026, though it remains unconfirmed by the company. It is expected to cover Q2 2026 results. The date is consistent with the company’s typical early-August reporting pattern and is scheduled before the market opens.
Buy LLY or NVO in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.